studies

metastatic/advanced RCC (mRCC) - 2nd line (L2), immune chekpoint inhibitors vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCheckMate 025, 2015 0.73 [0.57; 0.93] 0.73[0.57; 0.93]CheckMate 025, 201510%821NAnot evaluable progression or deaths (PFS)detailed resultsCheckMate 025, 2015 0.88 [0.75; 1.03] 0.88[0.75; 1.03]CheckMate 025, 201510%821NAnot evaluable objective responses (ORR)detailed resultsCheckMate 025, 2015 5.98 [3.68; 9.72] 5.98[3.68; 9.72]CheckMate 025, 201510%821NAnot evaluable TRAE (any grade)detailed resultsCheckMate 025, 2015 0.50 [0.34; 0.74] 0.50[0.34; 0.74]CheckMate 025, 201510%803NAnot evaluable TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 0.40 [0.29; 0.55] 0.40[0.29; 0.55]CheckMate 025, 201510%803NAnot evaluable TRAE leading to death (grade 5)detailed resultsCheckMate 025, 2015 0.24 [0.01; 5.42] 0.24[0.01; 5.42]CheckMate 025, 201510%803NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 025, 2015 0.55 [0.34; 0.88] 0.55[0.34; 0.88]CheckMate 025, 201510%803NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 0.21 [0.09; 0.48] 0.21[0.09; 0.48]CheckMate 025, 201510%803NAnot evaluable Cough TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 0.98 [0.02; 49.40] 0.98[0.02; 49.40]CheckMate 025, 201510%803NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 0.49 [0.09; 2.67] 0.49[0.09; 2.67]CheckMate 025, 201510%803NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 0.98 [0.28; 3.40] 0.98[0.28; 3.40]CheckMate 025, 201510%803NAnot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 0.98 [0.02; 49.40] 0.98[0.02; 49.40]CheckMate 025, 201510%803NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 1.47 [0.24; 8.85] 1.47[0.24; 8.85]CheckMate 025, 201510%803NAnot evaluable Epistaxis TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 0.98 [0.02; 49.40] 0.98[0.02; 49.40]CheckMate 025, 201510%803NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 0.89 [0.37; 2.11] 0.89[0.37; 2.11]CheckMate 025, 201510%803NAnot evaluable Mucosal inflammation TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 0.04 [0.00; 0.67] 0.04[0.00; 0.67]CheckMate 025, 201510%803NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 0.32 [0.03; 3.13] 0.32[0.03; 3.13]CheckMate 025, 201510%803NAnot evaluable Peripheral oedema TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 0.24 [0.01; 5.42] 0.24[0.01; 5.42]CheckMate 025, 201510%803NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 0.53 [0.19; 1.44] 0.53[0.19; 1.44]CheckMate 025, 201510%803NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 0.98 [0.02; 49.40] 0.98[0.02; 49.40]CheckMate 025, 201510%803NAnot evaluable Rash TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 0.65 [0.11; 3.91] 0.65[0.11; 3.91]CheckMate 025, 201510%803NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 0.03 [0.00; 0.46] 0.03[0.00; 0.46]CheckMate 025, 201510%803NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-06-02 07:46 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 80 - treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743